生物相似药：全球市场

全球生物相似药市场规模预计将从 2023 年的 238 亿美元和 2024 年的 285 亿美元成长到 2029 年的 692 亿美元，预测期内的复合年增长率为 19.4%。

预计欧洲生物相似药市场规模将从 2024 年的 130 亿美元成长到 2029 年的 316 亿美元，预测期内的复合年增长率为 19.4%。北美生物相似药市场预计将从 2024 年的 92 亿美元成长到 2029 年的 229 亿美元，复合年增长率为 20.1%。

本报告调查了全球生物相似药市场，并提供了市场概况的摘要、市场影响因素和市场机会的分析、法律制度、新兴技术和技术发展的趋势、市场规模的趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 研究范围
• 市场分析

第二章 市场概况

• 生物相似药术语
• 生物相似药关键术语
• 世界卫生组织生物相似药评估指南
• 药物警戒/核准后监控
• 生物相似药与生技改良药
• 常见的生物相似药类型
• 重组激素
• 重组生长因子
• 单株抗体（mAb）
• 融合蛋白
• 干扰素
• 低分子量肝素 (LMWH)

第三章 市场动态

• 市场驱动因素
• 主要生技药品专利到期
• 成本效益和降低医疗成本
• 市场限制
• 智慧财产权和法律问题
• 製造和供应链的复杂性
• 市场机会
• 提高访问量、采用率和认知度
• 新兴市场

第 4 章 新兴技术

• 高阶分析技术
• 免洗生物反应器
• 细胞株工程和表现系统

第五章市场区隔分析

• 细分市场
• 全球生物相似药市场按产品类型划分
• 单株抗体
• 重组生长因子
• 重组激素
• 融合蛋白
• 其他的
• 全球生物相似药市场（依治疗用途划分）
• 癌症及相关疾病
• 自体免疫和发炎性疾病
• 糖尿病
• 贫血
• 生长激素缺乏
• 其他的
• 地理分布
• 全球生物相似药市场按地区划分
• 市场规模及预测
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第六章 竞争格局及专利分析

• 概述
• 主要市场领导
• 新兴企业
• 战略分析
• 问题和未来趋势
• 专利分析
• 有利于品牌生技药品的专利监管
• 市场独占性

第七章 监管方面

• 概述
• 欧洲
• 美国
• 排他性原则
• 中国

第 8 章全球生物相似药市场的永续性：ESG 视角

• ESG：简介
• 市场中的 ESG 表现
• 生物相似药产业的 ESG 实践
• 环境绩效
• BCC的结语

第 9 章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• ACCORD BIOPHARMA INC.
• ALVOTECH
• AMGEN INC.
• AMNEAL PHARMACEUTICALS LLC.
• BIOCON BIOLOGICS LTD.
• BIOGEN
• CELLTRION INC.
• COHERUS BIOSCIENCES
• FRESENIUS KABI AG
• LILLY
• PFIZER INC.
• SAMSUNG BIOEPIS
• SANDOZ GROUP AG
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.

The global biosimilars market was valued at $23.8 billion in 2023. The market is expected to grow from $28.5 billion in 2024 to $69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.

The European biosimilars market is expected to grow from $13.0 billion in 2024 to $31.6 billion by 2029, at a CAGR of 19.4% from 2024 through 2029.

The North American biosimilars market is expected to grow from $9.2 billion in 2024 to $22.9 billion by 2029, at a CAGR of 20.1% from 2024 through 2029.

Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization's business segments, financials, product portfolios and recent developments.

Report Includes

• 142 data tables and 74 additional tables
• An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
• Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
• Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• An analysis of key patent publications, grants and applications in biosimilars
• Analysis of the competitive landscape featuring companies' market shares, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
• Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Insights

Chapter 2 Market Overview

• Introduction
• Terminology of Biosimilars
• Key Terms in Biosimilars
• WHO Guidelines on Evaluation of Biosimilars
• Pharmacovigilance/Post-Approval Monitoring
• Biosimilars Vs. Biobetters
• Popular Types of Biosimilars
• Recombinant Hormones
• Recombinant Growth Factors
• Monoclonal Antibodies (mAbs)
• Fusion Proteins
• Interferons
• Low Molecular Weight Heparins (LMWHs)

Chapter 3 Market Dynamics

• Introduction
• Market Drivers
• Patent Expirations of Major Biologics
• Cost-effectiveness and Healthcare Savings
• Market Restraints
• Intellectual Property and Legal Issues
• Manufacturing and Supply Chain Complexities
• Market Opportunities
• Increasing Access, Adoption and Awareness
• Emerging Markets

Chapter 4 Emerging Technologies

• Advanced Analytical Techniques
• Single-use Bioreactors
• Cell Line Engineering and Expression Systems

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Global Biosimilars Market, by Product Type
• Monoclonal Antibodies
• Recombinant Growth Factors
• Recombinant Hormones
• Fusion Protein
• Others
• Global Biosimilars Market, by Therapeutic Application
• Cancer and Related Disorders
• Autoimmune and Inflammatory Diseases
• Diabetes
• Anemia
• Growth Hormone Deficiency
• Other Diseases
• Geographic Breakdown
• Global Biosimilars Market, by Region
• Market Size and Forecast
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 6 Competitive Landscape and Patent Analysis

• Overview
• Key Market Leaders
• Emerging Players
• Strategic Analysis
• Challenges and Future Trends
• Patent Analysis
• Patent Regulations in Favor of Branded Biologics
• Market Exclusivity

Chapter 7 Regulatory Aspects

• Overview
• Biosimilar Regulations in Europe
• Biosimilar Regulations in the U.S.
• Principle of Exclusivity
• Biosimilar Regulations in China

Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective

• Introduction to ESG
• ESG Performance in the Market
• ESG Practices in the Biosimilars Industry
• Environmental Performance
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ACCORD BIOPHARMA INC.
• ALVOTECH
• AMGEN INC.
• AMNEAL PHARMACEUTICALS LLC.
• BIOCON BIOLOGICS LTD.
• BIOGEN
• CELLTRION INC.
• COHERUS BIOSCIENCES
• FRESENIUS KABI AG
• LILLY
• PFIZER INC.
• SAMSUNG BIOEPIS
• SANDOZ GROUP AG
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.

List of Tables

• Summary Table : Global Biosimilars Market, by Region, Through 2029
• Table 1 : Differences Between Generic and Biosimilar Drugs
• Table 2 : Terminology Related to Biosimilars
• Table 3 : Biosimilars Vs. Biobetters
• Table 4 : Examples of Approved Biobetters
• Table 5 : Representative Biobetters in Clinical Trials
• Table 6 : Key Developments in Biosimilar Recombinant Hormones
• Table 7 : Key Developments in Biosimilar Recombinant Growth Factors
• Table 8 : Key Developments in Biosimilar Monoclonal Antibodies
• Table 9 : Key Developments in Enbrel (Etanercept) Biosimilars
• Table 10 : Key Developments in Biosimilar Interferons
• Table 11 : Key Developments in LMWHs Biosimilars
• Table 12 : Global Biosimilars Market, by Product Type, Through 2029
• Table 13 : EMA Approved Biosimilar Monoclonal Antibodies
• Table 14 : FDA Approved Biosimilar Monoclonal Antibodies
• Table 15 : Global Biosimilar Monoclonal Antibodies Market, by Region, Through 2029
• Table 16 : Global Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 17 : Global Trastuzumab Biosimilars Market, by Region, Through 2029
• Table 18 : Global Rituximab Biosimilars Market, by Region, Through 2029
• Table 19 : Global Adalimumab Biosimilars Market, by Region, Through 2029
• Table 20 : Global Bevacizumab Biosimilars Market, by Region, Through 2029
• Table 21 : Global Infliximab Biosimilars Market, by Region, Through 2029
• Table 22 : EMA Approved Recombinant Growth Factors Biosimilars
• Table 23 : FDA Approved Recombinant Growth Factors Biosimilars
• Table 24 : Global Recombinant Growth Factors Biosimilars Market, by Region, Through 2029
• Table 25 : Global Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 26 : Global Filgrastim Biosimilars Market, by Region, Through 2029
• Table 27 : Global Epoetin Alfa Biosimilars Market, by Region, Through 2029
• Table 28 : Global Pegfilgrastim Biosimilars Market, by Region, Through 2029
• Table 29 : EMA Approved Recombinant Hormones Biosimilars
• Table 30 : FDA Approved Recombinant Hormones Biosimilars
• Table 31 : Global Recombinant Hormones Biosimilars Market, by Region, Through 2029
• Table 32 : Global Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 33 : Global Insulin Biosimilars Market, by Region, Through 2029
• Table 34 : Global Somatotropin Biosimilars Market, by Region, Through 2029
• Table 35 : Global Teriparatide Biosimilars Market, by Region, Through 2029
• Table 36 : Global Follitropin Alfa Biosimilars Market, by Region, Through 2029
• Table 37 : Global Fusion Protein Biosimilars Market, by Region, Through 2029
• Table 38 : Global Other Biosimilars Market, by Region, Through 2029
• Table 39 : Global Biosimilars Market, by Therapeutic Application, Through 2029
• Table 40 : Global Cancer and Related Disorders Market in Biosimilars, by Region, Through 2029
• Table 41 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, Through 2029
• Table 42 : Global Diabetes Market in Biosimilars, by Region, Through 2029
• Table 43 : Global Anemia Market in Biosimilars, by Region, Through 2029
• Table 44 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, Through 2029
• Table 45 : Global Other Diseases Market in Biosimilars, by Region, Through 2029
• Table 46 : Global Biosimilars Market, by Region, Through 2029
• Table 47 : North American Biosimilars Market, by Country, Through 2029
• Table 48 : North American Biosimilars Market, by Product Type, Through 2029
• Table 49 : North American Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 50 : North American Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 51 : North American Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 52 : North American Biosimilars Market, by Therapeutic Application, Through 2029
• Table 53 : Biosimilar Approvals in the U.S.
• Table 54 : U.S. Biosimilars Market, by Product Type, Through 2029
• Table 55 : U.S. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 56 : U.S. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 57 : U.S. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 58 : U.S. Biosimilars Market, by Therapeutic Application, Through 2029
• Table 59 : Canadian Biosimilars Market, by Product Type, Through 2029
• Table 60 : Canadian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 61 : Canadian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 62 : Canadian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 63 : Canadian Biosimilars Market, by Therapeutic Application, Through 2029
• Table 64 : Mexican Biosimilars Market, by Product Type, Through 2029
• Table 65 : Mexican Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 66 : Mexican Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 67 : Mexican Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 68 : Mexican Biosimilars Market, by Therapeutic Application, Through 2029
• Table 69 : Biosimilar Approvals in Europe
• Table 70 : European Biosimilars Market, by Country, Through 2029
• Table 71 : European Biosimilars Market, by Product Type, Through 2029
• Table 72 : European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 73 : European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 74 : European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 75 : European Biosimilars Market, by Therapeutic Application, Through 2029
• Table 76 : German Biosimilars Market, by Product Type, Through 2029
• Table 77 : German Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 78 : German Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 79 : German Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 80 : German Biosimilars Market, by Therapeutic Application, Through 2029
• Table 81 : U.K. Biosimilars Market, by Product Type, Through 2029
• Table 82 : U.K. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 83 : U.K. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 84 : U.K. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 85 : U.K. Biosimilars Market, by Therapeutic Application, Through 2029
• Table 86 : French Biosimilars Market, by Product Type, Through 2029
• Table 87 : French Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 88 : French Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 89 : French Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 90 : French Biosimilars Market, by Therapeutic Application, Through 2029
• Table 91 : Italian Biosimilars Market, by Product Type, Through 2029
• Table 92 : Italian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 93 : Italian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 94 : Italian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 95 : Italian Biosimilars Market, by Therapeutic Application, Through 2029
• Table 96 : Spanish Biosimilars Market, by Product Type, Through 2029
• Table 97 : Spanish Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 98 : Spanish Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 99 : Spanish Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 100 : Spanish Biosimilars Market, by Therapeutic Application, Through 2029
• Table 101 : Rest of European Biosimilars Market, by Product Type, Through 2029
• Table 102 : Rest of European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 103 : Rest of European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 104 : Rest of European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 105 : Rest of European Biosimilars Market, by Therapeutic Application, Through 2029
• Table 106 : Asia-Pacific Biosimilars Market, by Country, Through 2029
• Table 107 : Asia-Pacific Biosimilars Market, by Product Type, Through 2029
• Table 108 : Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 109 : Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 110 : Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 111 : Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
• Table 112 : Biosimilar Approvals in China
• Table 113 : Chinese Biosimilars Market, by Product Type, Through 2029
• Table 114 : Chinese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 115 : Chinese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 116 : Chinese Recombinant Hormones Biosimilars, by Product Type, Through 2029
• Table 117 : Chinese Biosimilars Market, by Therapeutic Application, Through 2029
• Table 118 : Japanese Biosimilars Market, by Product Type, Through 2029
• Table 119 : Japanese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 120 : Japanese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 121 : Japanese Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 122 : Japanese Biosimilars Market, by Therapeutic Application, Through 2029
• Table 123 : Indian Biosimilars Market, by Product Type, Through 2029
• Table 124 : Indian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 125 : Indian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 126 : Indian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 127 : Indian Biosimilars Market, by Therapeutic Application, Through 2029
• Table 128 : Australian Biosimilars Market, by Product Type, Through 2029
• Table 129 : Australian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 130 : Australian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 131 : Australian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 132 : Australian Biosimilars Market, by Therapeutic Application, Through 2029
• Table 133 : South Korean Biosimilars Market, by Product Type, Through 2029
• Table 134 : South Korean Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 135 : South Korean Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 136 : South Korean Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 137 : South Korean Biosimilars Market, by Therapeutic Application, Through 2029
• Table 138 : Rest of Asia-Pacific Biosimilars Market, by Product Type, Through 2029
• Table 139 : Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 140 : Rest of Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 141 : Rest of Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 142 : Rest of Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
• Table 143 : RoW Biosimilars Market, by Product Type, Through 2029
• Table 144 : RoW Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
• Table 145 : RoW Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
• Table 146 : RoW Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
• Table 147 : RoW Biosimilars Market, by Therapeutic Application, Through 2029
• Table 148 : Select Strategic Alliances in the Biosimilars Industry, 2022-2024
• Table 149 : Leading Biosimilars Companies, by Revenue, 2023
• Table 150 : U.S. Patent Expirations and Biosimilars, 2024
• Table 151 : Pending Biosimilar Patent Litigation, 2024
• Table 152 : FDA Guidelines on Biosimilars, February 2021
• Table 153 : Biosimilar Products Approved in China, 2024
• Table 154 : Key Focus Areas in ESG Metrics
• Table 155 : ESG Rankings for Key Players in Biosimilars Market, 2024*
• Table 156 : Information Sources in This Report
• Table 157 : Glossary of Terms Used in the Biosimilars Market
• Table 158 : Accord BioPharma Inc.: Company Snapshot
• Table 159 : Accord BioPharma Inc.: Product Portfolio
• Table 160 : Accord BioPharma Inc.: News/Key Developments, 2024
• Table 161 : Alvotech: Company Snapshot
• Table 162 : Alvotech: Financial Performance, FY 2022 and 2023
• Table 163 : Alvotech: Product Portfolio
• Table 164 : Alvotech: News/Key Developments, 2024
• Table 165 : Amgen Inc.: Company Snapshot
• Table 166 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 167 : Amgen Inc.: Product Portfolio
• Table 168 : Amgen Inc.: News/Key Developments, 2022-2023
• Table 169 : Amneal Pharmaceuticals LLC.: Company Snapshot
• Table 170 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2022 and 2023
• Table 171 : Amneal Pharmaceuticals LLC.: Product Portfolio
• Table 172 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2024
• Table 173 : Biocon Biologics Ltd.: Company Snapshot
• Table 174 : Biocon Biologics Ltd.: Financial Performance, FY 2022 and 2023
• Table 175 : Biocon Biologics Ltd.: Product Portfolio
• Table 176 : Biocon Biologics Ltd.: News/Key Developments, 2022-2024
• Table 177 : Biogen: Company Snapshot
• Table 178 : Biogen: Financial Performance, FY 2022 and 2023
• Table 179 : Biogen: Product Portfolio
• Table 180 : Biogen: News/Key Developments, 2023-2024
• Table 181 : Celltrion Inc.: Company Snapshot
• Table 182 : Celltrion Inc.: Financial Performance, FY 2022 and 2023
• Table 183 : Celltrion Inc.: Product Portfolio
• Table 184 : Celltrion Inc.: News/Key Developments, 2023-2024
• Table 185 : Coherus BioSciences: Company Snapshot
• Table 186 : Coherus BioSciences: Financial Performance, FY 2022 and 2023
• Table 187 : Coherus BioSciences: Product Portfolio
• Table 188 : Coherus BioSciences: News/Key Developments, 2024
• Table 189 : Fresenius Kabi AG: Company Snapshot
• Table 190 : Fresenius Kabi AG: Financial Performance, FY 2022 and 2023
• Table 191 : Fresenius Kabi AG: Product Portfolio
• Table 192 : Fresenius Kabi AG: News/Key Developments, 2024
• Table 193 : Lilly: Company Snapshot
• Table 194 : Lilly: Financial Performance, FY 2022 and 2023
• Table 195 : Lilly: Product Portfolio
• Table 196 : Lilly: News/Key Developments, 2022-2023
• Table 197 : Pfizer Inc.: Company Snapshot
• Table 198 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
• Table 199 : Pfizer Inc.: Product Portfolio
• Table 200 : Pfizer Inc.: News/Key Developments, 2023
• Table 201 : Samsung Bioepis: Company Snapshot
• Table 202 : Samsung Bioepis: Product Portfolio
• Table 203 : Samsung Bioepis: News/Key Developments, 2023-2024
• Table 204 : Sandoz Group AG: Company Snapshot
• Table 205 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
• Table 206 : Sandoz Group AG: Product Portfolio
• Table 207 : Sandoz Group AG: News/Key Developments, 2024
• Table 208 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 209 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
• Table 210 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 211 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2024
• Table 212 : Viatris Inc.: Company Snapshot
• Table 213 : Viatris Inc.: Financial Performance, FY 2022 and 2023
• Table 214 : Viatris Inc.: Product Portfolio
• Table 215 : Viatris Inc.: News/Key Developments, 2022

List of Figures

• Summary Figure : Share of Global Market for Biosimilars, by Region, 2023
• Figure 1 : Snapshot of the Market Dynamics for Biosimilars
• Figure 2 : Share of Global Market for Biosimilars, by Product Type, 2023
• Figure 3 : Global Biosimilar Monoclonal Antibodies Market, by Region, 2021-2029
• Figure 4 : Global Recombinant Growth Factors Biosimilars Market, by Region, 2021-2029
• Figure 5 : Global Recombinant Hormones Biosimilars Market, by Region, 2021-2029
• Figure 6 : Global Fusion Protein Biosimilars Market, by Region, 2021-2029
• Figure 7 : Global Other Biosimilars Market, by Region, 2021-2029
• Figure 8 : Share of Global Market for Biosimilars, by Therapeutic Application, 2023
• Figure 9 : Global Cancer and Related Disorders Market in Biosimilars, 2021-2029
• Figure 10 : Global Cancer and Related Disorders Market in Biosimilars, by Region, 2021-2029
• Figure 11 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, 2021-2029
• Figure 12 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, 2021-2029
• Figure 13 : Global Diabetes Market in Biosimilars, 2021-2029
• Figure 14 : Global Diabetes Market in Biosimilars, by Region, 2021-2029
• Figure 15 : Global Anemia Market in Biosimilars, 2021-2029
• Figure 16 : Global Anemia Market in Biosimilars, by Region, 2021-2029
• Figure 17 : Global Growth Hormone Deficiency Market in Biosimilars, 2021-2029
• Figure 18 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, 2021-2029
• Figure 19 : Global Other Diseases Market in Biosimilars, 2021-2029
• Figure 20 : Global Other Diseases Market in Biosimilars, by Region, 2021-2029
• Figure 21 : Share of Global Market for Biosimilars, by Region, 2023
• Figure 22 : Global Biosimilars Market, by Region, 2021-2029
• Figure 23 : Share of North American Market for Biosimilars, by Country, 2023
• Figure 24 : U.S. Biosimilars Market, 2021-2029
• Figure 25 : Canadian Biosimilars Market, 2021-2029
• Figure 26 : Mexican Biosimilars Market, 2021-2029
• Figure 27 : Share of European Market for Biosimilars, by Country, 2023
• Figure 28 : German Biosimilars Market, 2021-2029
• Figure 29 : U.K. Biosimilars Market, 2021-2029
• Figure 30 : French Biosimilars Market, 2021-2029
• Figure 31 : Italian Biosimilars Market, 2021-2029
• Figure 32 : Spanish Biosimilars Market, 2021-2029
• Figure 33 : Rest of European Biosimilars Market, 2021-2029
• Figure 34 : Share of Asia-Pacific Market for Biosimilars, by Country, 2023
• Figure 35 : Chinese Biosimilars Market, 2021-2029
• Figure 36 : Japanese Biosimilars Market, 2021-2029
• Figure 37 : Indian Biosimilars Market, 2021-2029
• Figure 38 : Australian Biosimilars Market, 2021-2029
• Figure 39 : South Korean Biosimilars Market, 2021-2029
• Figure 40 : Rest of Asia-Pacific Biosimilars Market, 2021-2029
• Figure 41 : Snapshot of the ESG Pillars
• Figure 42 : Advantages of ESG for Biosimilar Companies
• Figure 43 : Share of Biotech Companies Providing ESG Disclosure, 2022
• Figure 44 : Share of ESG Disclosure, by Location, 2022
• Figure 45 : Alvotech: Revenue Share, by Country/Region, FY 2023
• Figure 46 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 47 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2023
• Figure 48 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 49 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 50 : Biogen: Revenue Share, by Business Unit, FY 2023
• Figure 51 : Biogen: Revenue Share, by Country/Region, FY 2023
• Figure 52 : Fresenius Kabi AG: Revenue Share, by Business Unit, FY 2023
• Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023
• Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023
• Figure 55 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 56 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 57 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
• Figure 58 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
• Figure 59 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 60 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 61 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023